66 results about "Amidohydrolase" patented technology

The present invention relates to novel oxime carbamyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase. These pharmaceutical compositions are useful for the treatment of conditions which can be effected by inhibiting fatty acid amide hydrolase including, but not limited to, neuropathic pain, emesis, anxiety, altering feeding behaviors, movement disorders, glaucoma, brain injury, and cardiovascular disease.

The invention discloses a detection kit for determining the content of creatinine in serum by an enzymic method. The detection kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 contains 3-10g/L of buffering solution with the pH value being 7.5-8.0, 0.2-0.5g/L of EDTA, 0.5-2g/L of N-ethyl-N-(2-hydroxyl-3-sulfopropyl) m-toluidine sodium salt, 1 per mill-5 per mill of a surface active agent, 0.2-1g/L of sarcosine oxidase, 1-5KU/L of ascorbate oxidase, 2-5KU/L of creatinase and 0.5-1g/L of a stabilizing agent; the reagent R2 contains 3-10g/L of buffering solution with the pH value being 7.5-8.0, 0.1-0.5g/L of 4-aminoantipyrine, 0.1-0.4g/L of potassium ferricyanide, 2-8g/L of creatininase amidohydrolase, 1-6KU/L of peroxidase and 0.5-2g/L of a preservative. The detection kit disclosed by the invention is excellent in stability, strong in interference resistance and high in clinical application value.

The invention relates to the clone of amidohydrolase, and the construction, zymoprotein expression and industrial application of engineering bacteria, belongs to the field of bioengineering technology and mainly aims to solve the problems that amidohydrolase produced by natural bacteria is low in enzyme activity, low in bacterial concentration and difficult for production application. On the basis that the hydrolase is produced by fermenting Delftiatsuruhatensis in Delftia, an amidohydrolase gene is cloned to establish a full set of process of the fermentation, and inducible expression, and industrial production of the Escherichia coli gene engineering bacteria. Through the gene engineering modification, the amidase activity is over 3000 u/l, much higher than 300 u/l of the original strain; the actual application shows that the enzyme has a wide application scope, can be applied the production of side chains of statins, the production cost is greatly reduced and the realization of green chemistry is promoted.

Compounds of formula (I): wherein, Z is -N-or>CH; R<1> is -H or -C1-4alkyl; Ar<1> is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring member with one or two R moieties; where each R moiety is independently selected from the group consisting of -C1-4alkyl, -C2-4alkenyl, -OH, -OC1-4alkyl, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkyl, -OSO2C1-4alkyl, -CO2C1-4alkyl, -CO2H, -COC1-4alkyl, -N(R)R<c>, -SO2NRR<c>, -NRSO2R<c>, -C(=O)NRR<c>, -NO2, and -CN, wherein R and R<c> are each independently -H or -C1-4alkyl; and Ar<2> is defined in the claims are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

The invention relates to the field of biochemical engineering, in particular to a novel process for preparing L-amino acid and D-amino acid by direct biocatalysis and hydrolysis resolution for DL-N-acetyl amino acid esters. DL-N-acetyl amino acid esters is used as substrate, enzyme including amide hydrolase and ester hydrolase is used as catalyst, wherein the enzyme is achieved by fermenting aspergillus oryzae Lb3085, de-ionized water is utilized as solvent and added in an enzyme catalysis reactor, and L-N-acetyl amino acid esters of the substrate is hydrolyzed into L-amino acid, D-N-acetyl amino acid esters of the substrate is hydrolyzed into D-N-acetyl amino acid, thereby resolution is realized. The resolution technique of 'one bacterium two enzymes' can efficiently reduce operating intermediate process, and achieve purposes of convenience and cleaning.

The invention belongs to the technical field of clinical in vitro diagnostic reagents and relates to a dry chemical reagent tablet for quantitatively measuring the concentration of creatinine and a preparation method of the dry chemical reagent tablet. The dry chemical reagent tablet comprises four laminations which are respectively a support layer, a color developing layer, a reagent layer and adiffusion layer distributed sequentially; and reagents in the reagent layer include a buffer system, a hydrophilic colloid, a creatine amidinohydrolase, sarcosine oxidase, peroxidase, a protective agent, a chelating agent, an activator and a surfactant; and reagents in the color developing layer include a chromogen, a creatine amidohydrolase, a hydrophilic colloid, and a surfactant. The dry chemical reagent tablet and the preparation method thereof of the invention have the advantages of simple operation process, high stability, high good repeatability and high accuracy of detection results, quantitative detection, wide linear range, simple and convenient preparation process, easiness in operation, low risk and low pollution. According to the dry chemical reagent tablet and the preparationmethod of the dry chemical reagent tablet of the invention, the reagents do not need to be prepared, and samples can be directly added dropwise; and the reagent tablet is dry and is free of moisture;the diffusion layer has a filtering function, so that hemolysis, bilirubin and ascorbic acid samples exert no significant interference on measurement results.

Described herein is a method for determining an effective dose of a composition for inhibiting fatty acid amide hydrolase activity in vivo, by first administering to a subject a dose of a test composition, and subsequently assessing if the level of a fatty acid amide in the subject increases. Also described, is a method for optimizing therapeutic efficacy for treatment of anxiety, depression, pain, or a metabolic disorder by increasing or decreasing a dose of a fatty amide hydrolase inhibitor according to a patient's fatty acid amide levels. In addition, pharmaceutical compositions are described, which contain fatty acid amide hydrolase inhibitors effective for increasing a FAA level in a patient.

Disclosed are compounds that may be used to inhibit the action of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH/MAGL.

Disclosed herein are methods for treating energy metabolism disorders by administering a composition containing a therapeutically effective amount of a fatty acid amide hydrolase inhibitor. The composition can also be administered to reduce body fat, body weight, or caloric intake.

The invention provides a recombinant amide hydrolase gene and application thereof. The recombinant amide hydrolase gene comprises a nucleotide sequence as shown in SEQ ID No. 1. The invention also provides a recombinant vector, a recombinant cell, a preparation method of recombinant amide hydrolase and the recombinant amide hydrolase prepared by the preparation method. The recombinant amide hydrolase gene provided by the invention has high expression efficiency in recipient cells, and provides conditions for industrialized production of amide hydrolase; the preparation and purification method of the amide hydrolase is simple and efficient; and the obtained amide hydrolase has good catalytic activity and stability and has practical application value in production.

The invention belongs to the technical field of bioengineering, and relates to breeding of industrial microorganisms, in particular to a strain construction method for displaying ureido amidohydrolaseon the surface of saccharomyces cerevisiae cells by taking cwp2 as anchoring protein and application. The ACCD display strain is constructed by fusing the cwp2 anchoring protein and target protein UA, so that the urea degradation rate of yellow rice wine fermentation liquor reaches 89.9% or above, and the EC degradation rate is 56.4% or above; when the ACCD strain is cultured for 72 hours, the enzyme activity of about 12,000 U/g (stem cells) can be achieved, and compared with commercial urease, displayed enzyme has higher thermal stability and tolerance; and when the ACCD is used as an enzymepreparation to treat the yellow rice wine fermentation liquor, the urea degradation rate and EC degradation rate are highest, the initial urea degradation rate can still be kept at 80% or above afterthe ACCD is repeatedly used ten times, and flavor substances of the yellow rice wine are not obviously changed before and after treatment. Therefore, the ACCD display enzyme strain has a wide marketprospect.

The invention discloses a pyrazinamide hydrolase, and an encoding gene and an application thereof. The hydrolase has an amino acid sequence represented as the SEQ ID No.1; and the encoding gene is a DNA molecule which has a nucleotide sequence represented as the SEQ ID No.2. The pyrazinamide hydrolase is high in enzyme activity and has good pH tolerance. The invention demonstrates a direction of therapy on patients, which has pyrazinamide resistance in vivo, by combining pyrazinamide with the pyrazinamide hydrolase.

Described herein, inter alia, are compositions and methods useful for inhibiting fatty acid amide hydrolase.

The present invention relates to an amide hydrolase which is with excellent thermostability and stereoselectively hydrolyzes an α-amino acid amide; a gene encoding the enzyme protein; a novel recombinant vector containing the gene; a transformant containing the recombinant vector; and a process for producing an L-α-amino acid using the transformant.

The invention discloses a creatinine detection reagent capable of resisting interference of medicines such as calcium dobesilate. The creatinine detection reagent comprises a first reagent and a second reagent, wherein the first reagent comprises 3-(N-morpholinyl)propanesulfonic acid, TOOS, gentamicin, sarcosine oxidase, creatinase, ascorbic acid oxidase and catalase, and the second reagent comprises 3-(N-morpholinyl)propanesulfonic acid, 4-AAP, creatininase amidohydrolase, peroxidase, preservative and potassium ferrocyanide; the first reagent and/or the second reagent further comprise/comprises piperidine oxygen radicals. According to the creatinine detection reagent provided by the invention, the interference effect of medicines such as calcium dobesilate can be reduced, the accuracy ofcreatinine detection in clinical detection is ensured, and a creatinine detection method with a wide linear range, strong medicine interference resistance and high accuracy is realized.